Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL126012 | 0.85 | ALDH1A1 (0.44) | MEN1KMT2ACYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL25137312 | 0.83 | MEN1 (0.44) | MEN1KMT2AHTTKCNN4CYP3A4 | |
| SCHEMBL11734333 | 0.80 | ALDH1A1 (0.52) | MEN1KMT2AHTTCYP3A4CYP2C9 | |
| SCHEMBL21120529 | 0.79 | MEN1 (0.41) | MEN1KMT2AHTTKCNN4CYP3A4 | |
| SCHEMBL13786373 | 0.77 | KCNN4 (0.46) | MEN1KMT2AHTTKCNN4CYP3A4 | |
| SCHEMBL10294024 | 0.76 | ALDH1A1 (0.55) | CYP2C19SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL27989762 | 0.76 | MEN1 (0.42) | MEN1KMT2AHTTKCNN4CYP3A4 | |
| SCHEMBL4033878 | 0.76 | MEN1 (0.42) | MEN1KMT2AHTTKCNN4CYP3A4 | |
| SCHEMBL18364997 | 0.75 | MEN1 (0.38) | MEN1KMT2AHTTKCNN4CYP3A4 | |
| SCHEMBL17576276 | 0.75 | MEN1 (0.38) | MEN1KMT2AHTTKCNN4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108441308-A | Intermetallic composite coating water-soluble high-efficient micro emulsion cutting fluid | 芜湖智为有道信息技术有限公司 | 2018-08-24 | — | — | CN | claimed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037447-B2 | Systems and processes for polymer production | NOVOMER, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118159625-A | Flame retardant composition, flame retardant resin composition, and molded article | 株式会社ADEKA | 2024-06-07 | — | — | CN | disclosed |
| CN-117946180-A | Chiral iridium complex and preparation method and application thereof | 南方科技大学 | 2024-04-30 | — | — | CN | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117580906-A | Nucleating agent composition, resin composition, molded article thereof, and method for producing resin composition | 株式会社ADEKA | 2024-02-20 | — | — | CN | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007119600-A1 | CARBAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | ROTH GERALD J | 2007-05-17 | — | — | US | disclosed |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC (US) | 2007-03-08 | — | — | US | disclosed |
| US-7071282-B2 | Benzimidazole diamine-based polyetherimide compositions and methods for making them | GENERAL ELECTRIC COMPANY (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1633802-A1 | BENZIMIDAZOLE DIAMINE-BASED POLYETHERIMIDE COMPOSITIONS AND METHODS FOR MAKING THEM | GENERAL ELECTRIC COMPANY (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108797-A1 | BENZIMIDAZOLE DIAMINE-BASED POLYETHERIMIDE COMPOSITIONS AND METHODS FOR MAKING THEM | GENERAL ELECTRIC COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040249117-A1 | Benzimidazole diamine-based polyetherimide compositions and methods for making them | GENERAL ELECTRIC COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111981-A1 | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, GPR119, MCHR2 | MEN1 2624/4885KMT2A 474/4885HTT 582/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | MEN1 3926/4885KMT2A 2302/4885HTT 2566/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | MEN1 3912/4885KMT2A 2732/4885HTT 4175/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | MEN1 3064/4885KMT2A 4262/4885HTT 2222/4885 |
| US-12037447-B2 | Systems and processes for polymer production | PGLS, APC, PHYKPL | MEN1 535/4885KMT2A 4550/4885HTT 254/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | MEN1 4315/4885KMT2A 3482/4885HTT 2429/4885 |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | AR, SHBG, NR5A1 | MEN1 2893/4885KMT2A 1470/4885HTT 1273/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | MEN1 4154/4885KMT2A 3170/4885HTT 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.